Pharmaceutical composition for ophthalmic use
AssigneeKabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo
InventorsToshihiko Matsuo, Masashi Kurimoto, Hiroshi Yamauchi
Life of this patent
Estimating the term…
Abstract
An ophthalmic pharmaceutical composition comprising trehalose as an effective ingredient and a pharmaceutically-acceptable carrier. The pharmaceutical composition is a safe, long-term continuously-administrable, therapeutic and/or prophylactic agent for the ophthalmologic clinical symptoms and signs in Sjögren syndrome.
Claims18
An ophthalmic pharmaceutical composition for treating and/or preventing the ophthalmologic clinical symptom and sign in dry eye including Sjögren syndrome, which comprises trehalose as an effective ingredient in an amount effective for such treatment and/or prevention, and a pharmaceutically-acceptable carrier, said trehalose having a purity of 99.0% or higher, d.s.b., and being substantially free from pyrogen.
A method for treating and/or preventing the ophthalmologic clinical symptom and sign in dry eye including Sjögren syndrome, comprising
- administering to a patient in need thereof an ophthalmic pharmaceutical composition comprising trehalose as an effective ingredient and a pharmaceutically-acceptable carrier said trehalose having a purity of 99.0% or higher, d.s.b., and being substantially free from pyrogen,
- whereby the ophthalmologic clinical symptom and sign are improved or even remitted, and such improvement or remission is capable of lasting days after completion of the administration.
Dependencies are inferred from the claim text.